Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 90

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 90
---
 in challenges with executive and employee retention, the extraordinary efforts required of the Company’s management team in connection with obtaining financing to remain viable and to cause the FDA to lift the clinical hold implemented in July 2024 and accept the submission of the IND in November 2024,

51

the Compensation Committee approved the repricing of awards to executive officers and employees and the grants of new awards to new hires and executive officers who were internally promoted, in each case on October 1, 2024, with a substantial portion of the awards to executive officers containing performance -basedvesting criteria, including with respect to the acceptance of the IND and obtaining additional financing. See “ — Equity Incentive Compensation” below. Equity Compensation Plan Information The following table sets forth information as of December 31, 2024 regarding shares of Common Stock that may be issued under our equity compensation plans. Such information includes equity compensation plans of Legacy CERo as of December 31, 2024 that were assumed by us in the Business Combination:

| Plan Category                                          |     |        Number of 
 Securities to be 
      Issued Upon 
      Exercise of 
      Outstanding 
         Options, 
         Warrants 
       and Rights |      |     | Weighted-average 
 Exercise Price   
 of Outstanding   
 Options,         
 Warrants,        
 Rights           |       |      |     |     Number of 
    Securities 
     Remaining 
 Available for 
        Future 
      Issuance 
  Under Equity 
  Compensation 
         Plans |
|:-------------------------------------------------------|:----|-----------------:|:-----|:----|:-----------------|------:|:-----|:----|--------------:|
| Equity compensation plans approved by stockholders     |     |           64,948 | ​(1) |     | $                | 10.00 | ​(2) |     |       414,073 |
| Equity compensation plans not approved by stockholders |     |                — |      |     |                  |     — |      |     |             — |
| Total                                                  |     |           64,948 |      |     | $                | 10.00 |      |     |       414,073 |

____________ (1)Includes 50shares subject to outstanding stock options under the 2016 Plan that were outstanding on December 31, 2023 (presented on an as -convertedbasis). No new awards may be granted under the 2016 Plan. (2)Reflects the weighted